Generic versions of semaglutide, widely recognized under the brand name Ozempic, are now available in Canada. Recently, Dr. Reddy’s Laboratories and Apotex Inc. received approval from Health Canada to manufacture these generics, leading to significant changes in availability and pricing for patients.
Health Canada’s Approval and Launch Timeline
As of three weeks ago, Health Canada authorized the production of generic semaglutide following the expiration of Novo Nordisk’s exclusivity rights in January. Dr. Reddy’s launched its generic version last week, while Apotex is expected to follow suit soon.
The Impact of Generic Ozempic in Canada
Canada’s move makes it the first G7 nation to approve a generic version of Ozempic. This is expected to enhance access for individuals suffering from Type 2 diabetes and obesity, conditions that affect many Canadians. Renowned pharmaceutical sciences professor Brian Rodrigues emphasized the generics’ potential to transform treatment options, particularly by reducing obesity rates and related health complications.
Cost and Accessibility
Generic medications typically reduce pharmaceutical costs. While exact prices for the new generics have not yet been released, initial estimates suggest they could be significantly lower than the brand-name version, which can range from $300 to $400 monthly. Experts predict that the first generics could be available at 75% to 85% of the brand’s cost. With further competition, this could drop to about 35% of the brand’s price, bringing costs down to around $100 per month.
Manufacturing Differences
While both generics and the brand name utilize the same active ingredient—semaglutide—the manufacturing processes differ. Ozempic involves complex biotechnological methods using yeast, making it costlier to produce. Generics, however, utilize a more streamlined chemical approach, assembling amino acids in a simpler manner akin to building with Lego blocks, resulting in similar effectiveness.
Safety and Effectiveness of Generic Versions
Generics are designed to be as safe and effective as their branded counterparts. Common and severe side effects associated with Ozempic, such as nausea and pancreatitis, are expected to be similar in the generic formulations. Health Canada confirmed that generics had undergone comprehensive evaluations to ensure safety, effectiveness, and quality standards are met.
Manufacturing Locations
Dr. Reddy’s operates multiple facilities in India, the UK, and Mexico, while Apotex has five Canadian facilities. However, Apotex will manufacture its semaglutide injectors in India due to the need for specialized sterile environments.
Future Developments
Health Canada is reviewing additional submissions for generic Ozempic, with multiple options expected to enter the market soon. This anticipated expansion could further drive down prices and increase accessibility.
- Health Canada approval for generic semaglutide.
- Launch of generics by Dr. Reddy’s and Apotex.
- Expected price reduction for patients.
- Similar side effects and safety profiles compared to the brand name.
As more generics hit the shelves, Canadians may benefit from improved access to treatment, potentially transforming the landscape of diabetes and obesity management.
